Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)
Clinical trial NCT02131233 · COMPLETED
Trial details
- NCT number
- NCT02131233
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2014-05-23
- Primary completion
- 2015-12-21
- Enrollment
- 802
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.